Zyla Life Sciences's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2020 to a ratio of 1.62, this is below the company average, and notable indication of worsening business environment. Average receivable collection period, for the Zyla Life Sciences in Mar 31 2020 quarter, has decreased to 225 days, compared to 344 days, in the Dec 31 2019 quarter.

If we take a look into Healthcare sector 517 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2020 from 3589 to 3590.

What is Receivable Turnover Ratio?
What is Zyla Life Sciences Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

EGLT Receivables Turnover Ratio	(Mar 31 2020) I. Quarter	(Dec 31 2019) IV. Quarter	(Sep 30 2019) III. Quarter	(Jun 30 2019) II. Quarter	(Mar 31 2019) I. Quarter
Y / Y Receivable Change	-20.04 %	199.5 %	124.63 %	114.37 %	151.31 %
Y / Y Revenue Change	204.52 %	-	174.57 %	196.04 %	0 %
Receivable Turnover Ratio (TTM)	1.62	1.06	2.45	2.19	1.72
EGLT's Total Ranking	# 3590	# 3589	# 3052	# 3584	# 3586
Accounts Receivable average collection period days	225	344	149	166	212
Seq. Receivable Change	20.47 %	-0.25 %	24.33 %	-46.48 %	351.24 %
Seq. Revenue Change	-	-	1.6 %	251.92 %	-26.31 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 211
Healthcare Sector	# 518
Overall Market	# 3590

Receivable Turnover Ratio Statistics
High	Average	Low
14.74	4.4	0.7
(Jun 30 2016)		(Mar 31 2015)

EGLT Company Profile • Back to EGLT Efficiency Comparisons • Compare EGLT Receivables Turnover Ratio to its Competitors

Financial Statements
Zyla Life Sciences's Accounts Receivable	$ 32 Millions	Visit EGLT's Balance sheet
Zyla Life Sciences's Sales TTM	$ 43 Millions	Visit EGLT's Income Statement
Sources of EGLT's Revenues		Visit EGLT's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
EGLT's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
EGLT's Growth Rates	EGLT's Roa	EGLT's Inventory Turnover Ratio	EGLT's Dividend Comparisons
EGLT's Profitability Ratios	EGLT's Roi	EGLT's Asset Turnover Ratio	EGLT's Dividend Growth
EGLT's Valuation Ratios	EGLT's Roe	EGLT's Financial Strength Ratios	EGLT's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2020, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2020	Receivable at quarter ending Mar 31 2020
Personalis Inc	3.70	$ 19.161 Millions	$ 5.180 Millions
Collegium Pharmaceutical Inc	3.69	$ 298.696 Millions	$ 81.010 Millions
Adm Tronics Unlimited Inc	3.68	$ 3.486 Millions	$ 0.949 Millions
Eagle Pharmaceuticals inc	3.67	$ 190.575 Millions	$ 51.912 Millions
Biodelivery Sciences International Inc	3.65	$ 129.898 Millions	$ 35.551 Millions
Coherus Oncology inc	3.65	$ 435.153 Millions	$ 119.118 Millions
Sangui Biotech International Inc	3.64	$ 0.046 Millions	$ 0.013 Millions
Xoma Royalty Corporation	3.64	$ 11.043 Millions	$ 3.033 Millions
Inovio Pharmaceuticals Inc	3.64	$ 5.632 Millions	$ 1.547 Millions
Elanco Animal Health Incorporated	3.64	$ 2,997.600 Millions	$ 824.300 Millions
Accelerate Diagnostics Inc	3.62	$ 9.889 Millions	$ 2.730 Millions
Reata Pharmaceuticals Inc	3.62	$ 20.100 Millions	$ 5.555 Millions
Biotricity Inc	3.62	$ 1.418 Millions	$ 0.392 Millions
Titan Pharmaceuticals Inc	3.59	$ 4.002 Millions	$ 1.115 Millions
Amag Pharmaceuticals inc	3.55	$ 320.608 Millions	$ 90.355 Millions
Teligent Inc	3.51	$ 60.221 Millions	$ 17.160 Millions
Oxford Immunotec Global Plc	3.50	$ 72.832 Millions	$ 20.834 Millions
Hookipa Pharma inc	3.49	$ 7.747 Millions	$ 2.218 Millions
Nektar Therapeutics	3.48	$ 136.968 Millions	$ 39.334 Millions
Amarin Corp Plcuk	3.47	$ 511.470 Millions	$ 147.235 Millions
Progyny Inc	3.39	$ 137.192 Millions	$ 40.508 Millions
Horizon Therapeutics Public Limited Company	3.38	$ 1,375.567 Millions	$ 406.434 Millions
Alimera Sciences Inc	3.38	$ 55.588 Millions	$ 16.445 Millions
Exagen Inc	3.38	$ 20.058 Millions	$ 5.937 Millions
Soligenix inc	3.36	$ 4.410 Millions	$ 1.310 Millions
Ligand Pharmaceuticals Incorporated	3.36	$ 109.959 Millions	$ 32.686 Millions
Biocardia Inc	3.36	$ 0.532 Millions	$ 0.158 Millions
Ocular Therapeutix Inc	3.29	$ 6.344 Millions	$ 1.927 Millions
Viewray Inc	3.29	$ 81.748 Millions	$ 24.831 Millions
Sientra Inc	3.27	$ 83.079 Millions	$ 25.413 Millions

Date modified: 2026-08-29T17:26:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.